Form 4: Tharimmune CEO Randy Milby Increases Stake in Company
SEC Form 4
Tharimmune CEO Randy Milby recently purchased additional shares of the company's common stock, increasing his beneficial ownership.
Summary
- On October 8, 2024, Randy Milby, the CEO of Tharimmune, Inc., acquired 1,500 shares of common stock at $2.085 per share.
- He also acquired 646 shares at $2.09 per share and 354 shares at $2.10 per share.
- Following these transactions, Milby's direct ownership in Tharimmune increased to 12,934 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a good sign, but the amount is relatively small and doesn't provide a strong signal.
Positives
- The CEO's purchase of additional shares could be interpreted as a positive signal about his confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the buying and selling activities of company executives and directors.
Stakeholder Impact
- The CEO's increased stake could positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 10/08/2024 | Date of common stock purchase transactions by Randy Milby |
| 10/10/2024 | Date of signature on the Form 4 filing |
Keywords
Tharimmune, Randy Milby, CEO, stock purchase, Form 4, beneficial ownership, THAR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.